Physiomesh and the Food and Drug Administration in Florida
Physiomesh went through bench testing and animal testing before it reached patients. It was not tested on humans before going into circulation — and under the FDA process that cleared it, it did not have to be. Understanding Physiomesh and the Food and Drug Administration in Florida means understanding that gap: a device can be legally sold, widely implanted, and later withdrawn, without the FDA ever having required a human trial of it.
Physiomesh is a flexible composite hernia mesh made by Ethicon, a Johnson & Johnson company. It was cleared in 2010 through the FDA’s 510(k) process as substantially equivalent to meshes already on the market, and Ethicon withdrew it worldwide in May 2016 after registry data showed higher recurrence and revision rates than comparable products. Patients across Florida who received the implant and later suffered complications have brought claims as part of the national Physiomesh lawsuits our firm handles within its mass tort practice.
This page explains the FDA’s role in the Physiomesh story — what the agency did and did not do, what ‘clearance’ actually means, and why none of it decides a patient’s legal claim. If you were harmed by Physiomesh, a free review with Rafferty Domnick Cunningham & Yaffa (RDCY) is where these general facts get applied to your implant and your records.
Have Questions About Physiomesh and the FDA in Florida?
Call us or request a case review by our experts.
The FDA’s Responsibility When Devices Fail
For those who have suffered from Physiomesh side effects or failure, the FDA is responsible for notifying the public about problems with medical devices. When the agency identifies a problem, it publishes safety information and can press companies to act — but the FDA’s tools are mostly informational and reactive. It does not design devices, it does not run its own clinical trials of them, and after a device is cleared it largely monitors reports submitted by manufacturers, hospitals, and patients. Anyone can search the FDA’s website for safety notices about a device, and that transparency matters — but it is a warning system, not a guarantee.
The limits of that system are part of the Physiomesh story. The data that ultimately drove Ethicon’s 2016 market withdrawal came from European hernia registries tracking real-world outcomes — recurrence and reoperation rates in actual patients. The FDA’s own adverse-event reporting captures only a portion of complications, and clinicians and patients often do not connect a failing implant to a reportable device problem until litigation or news coverage makes the connection for them. A Florida patient deciding whether the system failed them deserves that honest picture: the FDA cleared the device, monitored it imperfectly, and never ordered it off the market — the manufacturer withdrew it on registry data the agency did not generate.
Why the FDA Believed Physiomesh Was Reasonably Safe
The FDA treated Physiomesh as reasonably safe because Ethicon showed it was substantially equivalent to meshes already on the market. Ethicon requested clearance through the 510(k) process, a limited pathway built on comparison rather than independent proof. When the FDA receives a 510(k) submission, it generally has 90 days to respond before the company wants the product on the market. Parts of Physiomesh were very similar to existing meshes — most notably Ethicon’s own Proceed line — and because the device met the comparison standard the FDA applies, it was cleared for sale.
That logic has a structural weakness the lawsuits keep returning to: equivalence chains. A new device is compared to a predicate; that predicate was itself cleared by comparison to an earlier device; and small differences at each step can accumulate into a product that behaves quite differently in the body without ever being tested in people. Physiomesh’s coated composite construction differed from its predicates in ways plaintiffs say mattered enormously — layers meant to protect tissue allegedly kept the mesh from incorporating into the abdominal wall — yet the 510(k) framework had no mechanism that required human data to test that theory before implantation began.
How Could the FDA’s Physiomesh Clearance Affect Your Legal Options?
Call us or request a case review by our experts.
What the 510(k) Process Actually Is
The 510(k) pathway takes its name from the section of the Food, Drug, and Cosmetic Act that created it. It means a product was found substantially equivalent to a legally marketed device, so it can be sold without the clinical trials and extensive evidentiary support that a genuinely new, high-risk device would require. The 510(k) allows companies to reach the market faster by making products that differ incrementally from devices already cleared, and manufacturers understandably prefer it: the company submits its notification, the FDA reviews the comparison within its review window, and unless the agency sees a problem with the equivalence claim, clearance follows.
Devices considered lower-risk are eligible for this lighter pathway, and most surgical meshes have historically traveled it. The trade-off is deliberate — Congress designed 510(k) to avoid re-proving established technology — but it places enormous weight on the assumption that ‘similar to what we already sell’ means ‘performs like what we already sell.’ Hernia mesh litigation, Physiomesh included, is substantially an argument that for implantable devices left in the body for life, that assumption deserves more scrutiny than the process gives it.
Other Hernia Mesh Products and the Same Pathway
Physiomesh was not an outlier; it was typical. Many hernia mesh products reached the market before and alongside it through the same 510(k) route. The most similar product was Ethicon’s Proceed Mesh, which exists in several versions, and the UltraPro Hernia System and UltraPro mesh products were likewise submitted through 510(k). It is entirely possible — indeed routine — for a company to win clearance for a family of devices that differ modestly from one another, each new clearance resting on the last.
For a Florida patient, the practical point is that the brand name on your implant does not tell you how it was reviewed. Mesh products from multiple manufacturers — Ethicon, Atrium, Bard, and others — share the 510(k) history, and several share the litigation history too. Identifying your exact product from the operative report is what connects your case to the right body of evidence, whether that product is Physiomesh or a sibling device cleared the same way.
Cleared Is Not Approved: The Two FDA Pathways
The difference between a cleared medical device and an approved one is the process behind the word. Through 510(k), a device is cleared: the FDA found equivalence, the device may be sold and implanted, and the evidentiary bar is comparatively low. Devices that are approved went through premarket approval (PMA), a different and far more expensive route that can require human clinical testing and a direct showing of safety and effectiveness. When the FDA approves a device, it is saying the evidence supports the product’s safety to the agency’s standards; when it clears one, it is saying something much narrower.
That distinction carries legal weight as well as medical weight. PMA approval can preempt certain state-law claims; 510(k) clearance generally does not, which is why Physiomesh plaintiffs can pursue design-defect and failure-to-warn claims in court despite the FDA’s involvement. If you have questions about how the 510(k) process and the FDA’s role apply to your own Physiomesh implant in Florida, a lawyer who works with these records can walk through your operative report and explain where your case fits.
From Clearance to Withdrawal to the Courtroom
The timeline frames the legal claims. 2010: clearance on equivalence, no human trials. 2010 to 2016: implantation in hernia patients nationwide, including Florida, while complaints and revisions accumulated. May 2016: worldwide market withdrawal after European registry data showed higher recurrence and reoperation rates than peer products. Afterward: thousands of individual lawsuits, consolidated in federal court into the Physiomesh MDL in the Northern District of Georgia, where discovery tested what Ethicon knew about its coating design, its testing, and its complaint data, and when it knew it.
Plaintiffs allege the composite design — polypropylene mesh sealed between coating layers — prevented proper tissue incorporation, so the device shrank, folded, and failed, causing recurrence, chronic pain, infection, adhesions, and revision surgeries. Ethicon has defended the product and its testing. Those disputes are resolved on evidence, case by case and in bellwether proceedings, not by the fact of FDA clearance — a point the courts managing the MDL have had no difficulty with, because clearance was never a finding that the design was sound.
What Florida Physiomesh Patients Should Do Now
If you had hernia surgery in Florida roughly between 2010 and 2016 and later developed complications or needed another operation, start by identifying the implant. Your operative report and hospital implant records should name the product; if Physiomesh appears, preserve everything — revision operative reports and photographs, imaging, pathology on removed mesh, and your own timeline of symptoms and treatment. Revision findings are often the strongest evidence in these cases because they show the device’s actual condition in the body.
Then get the timing reviewed immediately. Physiomesh implants are years old by definition, Florida’s limitations period under section 95.11 is short, and the viability of a claim can turn on when complications appeared and when a revision identified the product. A free review sorts out product identification, deadlines, and where a claim belongs. Waiting helps no one — records get harder to obtain and options narrow with time.
Related Physiomesh and Mass Tort Pages
- Physiomesh Lawsuits
- Physiomesh Litigation
- Known Risks and Dangers of Physiomesh
- Florida Hernia Mesh Lawyer
- Mass Tort Lawyer
- Insulin Price-Fixing Claims
- Camp Lejeune Water Contamination
- Dupixent Lawsuits
Professional Recognition
Recognition applies to the named attorneys and selection years. See the linked profiles for details.
Frequently Asked Questions About Physiomesh and the FDA in Florida
Answers to common questions about how Physiomesh reached the market, what FDA clearance does and does not mean, why the product was withdrawn, and how Florida patients can pursue a claim. This is general information, not legal advice about a specific case.
What is Physiomesh?
Physiomesh — full name Physiomesh Flexible Composite Mesh — is a synthetic surgical mesh made by Ethicon, a Johnson & Johnson subsidiary, for hernia repair. It is built from polypropylene filaments woven into a mesh and coated on both sides with layers designed to separate the mesh from tissue and organs while the body grows into it. It was used in laparoscopic ventral and inguinal hernia repairs in Florida and across the country.
The coating is central to the lawsuits. Plaintiffs allege the layered construction prevented the mesh from incorporating into the abdominal wall as intended, so the device could shrink, fold, detach, and trigger the very complications — recurrence, pain, infection, and revision surgery — that hernia patients had surgery to avoid.
Sources: FDA: Surgical Mesh Used for Hernia Repair; MedlinePlus: Hernia.
How did the FDA allow Physiomesh onto the market?
Ethicon brought Physiomesh to market in 2010 through the FDA’s 510(k) premarket notification process. Under 510(k), a manufacturer does not have to prove a new device is safe and effective on its own terms; it has to show the device is substantially equivalent to a device already legally on the market — a ‘predicate’ device. Ethicon pointed to earlier meshes, including its own Proceed mesh, as predicates.
The FDA reviews the submission — the agency generally has 90 days to respond to a 510(k) notification — and if it agrees the devices are equivalent, it clears the new device for sale. That clearance is an administrative comparison to older products, not a clinical judgment that the new device was tested in patients and found safe.
Sources: FDA: Premarket Notification 510(k); FDA: Surgical Mesh Used for Hernia Repair.
Was Physiomesh tested on humans before it was sold?
Physiomesh went through bench testing and animal testing before reaching the market; it was not tested in human clinical trials before the FDA cleared it. That is not unusual for a 510(k) device — the process ordinarily does not require human trials at all — but it matters in these cases, because the failure modes patients reported, such as poor tissue incorporation and shrinkage inside the body over time, are exactly the kinds of problems bench and animal testing can miss.
Ethicon maintained that Physiomesh passed its bench and animal testing program. Plaintiffs answer that the testing did not replicate years inside a moving human abdomen, and that the company’s own complaint data after launch told a different story than its premarket testing did.
Sources: FDA: Premarket Notification 510(k); FDA: Premarket Approval (PMA).
What is the difference between an FDA-cleared device and an FDA-approved device?
The words sound interchangeable but describe two very different levels of review. A cleared device came through 510(k): the FDA found it substantially equivalent to a predicate device, usually without new human clinical data. An approved device came through premarket approval (PMA), the FDA’s most demanding pathway, which requires valid scientific evidence — typically including clinical investigations — giving reasonable assurance the device is safe and effective for its intended use.
Physiomesh was cleared, not approved. When patients hear that a device was ‘FDA approved,’ they reasonably assume the government tested it in people. For 510(k) devices like Physiomesh, that assumption is wrong, and closing that gap between public understanding and regulatory reality is a recurring theme in the litigation.
Sources: FDA: Premarket Notification 510(k); FDA: Premarket Approval (PMA).
Why was Physiomesh withdrawn from the market in 2016?
In May 2016, Ethicon voluntarily withdrew Physiomesh from the global market. The company pointed to data from two European hernia registries that had not yet been published, which showed higher recurrence and reoperation rates for Physiomesh used in laparoscopic ventral hernia repair compared with similar meshes. Ethicon said it could not identify a single cause and chose to withdraw the product rather than redesign it.
A voluntary withdrawal is not a formal FDA recall ordered on safety findings, and Ethicon did not concede the product was defective. For patients, though, the sequence matters: a device cleared in 2010 on equivalence to older meshes was off the market six years later because real-world outcomes were worse than the products it was compared against.
Sources: FDA: Surgical Mesh Used for Hernia Repair; FDA: Premarket Notification 510(k).
What complications have Physiomesh patients reported?
Patients and their surgeons have reported the complications the FDA associates with surgical mesh generally — pain, infection, hernia recurrence, adhesion of tissue to the mesh, and obstruction — along with problems specific to how Physiomesh behaved in the body: shrinkage and folding of the mesh, detachment from the tissue it was meant to reinforce, migration, and erosion. Many patients needed revision surgery to remove part or all of the device.
Revision is major surgery, not a quick fix, because tissue grows into mesh and removing it can damage the structures around it. If you had a Physiomesh implant and later developed chronic pain, a returning bulge, infection, or a second operation, those records are the foundation of any claim.
Sources: FDA: Surgical Mesh Used for Hernia Repair; MedlinePlus: Hernia.
What is the FDA’s role once a device like Physiomesh is on the market?
After clearance, the FDA’s role is largely watchful: it collects adverse-event reports from manufacturers, hospitals, and patients through its reporting systems, watches for safety signals, and can require postmarket studies, issue safety communications, or seek recalls when the data justify it. The agency does not re-test devices itself, and it depends heavily on what manufacturers and clinicians report.
That structure has limits that the Physiomesh history illustrates. Registry data from Europe — not FDA surveillance — drove the 2016 withdrawal, and adverse-event databases are widely understood to capture only a fraction of complications. Anyone can look up the FDA’s safety information for a device, and patients can file their own reports, but the system reacts to harm more than it prevents it.
Sources: FDA: Surgical Mesh Used for Hernia Repair; FDA: Premarket Notification 510(k).
Can I sue Ethicon even though the FDA cleared Physiomesh?
Yes. FDA clearance through 510(k) does not immunize a manufacturer from state product liability claims. Unlike the stricter PMA pathway — where federal approval can preempt some state claims — 510(k) clearance has generally not been held to block claims that a device was defectively designed or that the manufacturer failed to warn of risks it knew about. Physiomesh lawsuits proceed on exactly those theories.
The claims allege that Physiomesh’s coated, multi-layer design was unreasonably prone to failure, that Ethicon’s testing did not match how the device performed in patients, and that warnings to surgeons understated the recurrence and revision risks that later appeared in registry data. Clearance is a fact the defense will raise; it is not a verdict on any of those questions.
Sources: FDA: Premarket Notification 510(k); FDA: Premarket Approval (PMA).
Where are Physiomesh lawsuits being heard?
Federal Physiomesh cases were consolidated into a multidistrict litigation — In re: Ethicon Physiomesh Flexible Composite Hernia Mesh Products Liability Litigation, MDL No. 2782 — in the U.S. District Court for the Northern District of Georgia. Consolidation puts shared pretrial work, such as discovery into Ethicon’s design, testing, and FDA submissions, before a single judge, while each plaintiff’s case remains individual.
Florida patients can be part of that federal process, and claims are evaluated on the individual implant: the surgery, the complications, the revision findings, and the damages. Whether a particular case belongs in the MDL, in another court, or is resolved through negotiation depends on its own facts and timing, which is part of what a case review determines.
Sources: FDA: Surgical Mesh Used for Hernia Repair; Florida Statutes § 95.11, Online Sunshine.
How long do I have to bring a Physiomesh claim in Florida, and what does a review cost?
Florida’s limitations periods are set out in section 95.11, and most negligence-based claims must now be filed within two years, with the start of the period depending on facts such as the implant date, when complications appeared, and when a revision identified the product. Because Physiomesh was withdrawn in 2016, the dates in these cases are old — which makes an immediate deadline analysis essential rather than optional.
The review itself is free. We examine the implant and revision records, confirm the product, and give an honest assessment of whether a claim appears viable and timely. If you decide to proceed, the fee arrangement is put in writing before work begins; if the facts do not support a claim, we tell you that at no charge.
Sources: Florida Statutes § 95.11, Online Sunshine; MedlinePlus: Hernia.
Related Articles
- Can Dupixent Cause Cancer? What the Evidence Actually Shows
- Betting on Children: Why the Underage Gambling Mass Tort Demands Our Attention
- How To Document Damages: Treatment Courses, ADLs, And Pain Journals
- Why Contacting Counsel Before Record Requests Can Save Time And Reduce Cost
Need Help With a Physiomesh Case in Florida?
Call us or request a case review by our experts.
